1. Xhepa E, Tada T, Kufner S, et al. Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: a pooled analysis of the ISAR-LEFT-MAIN and ISAR-LEFT-MAIN 2 randomized clinical trials. Catheter Cardiovasc Interv. 2017; 89:1–10.
2. Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv. 2005; 64:442–448.
3. Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int. 2006; 70:1811–1817.
4. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 44:1393–1399.
5. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51:1419–1428.
6. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997; 103:368–375.
7. Oduncu V, Erkol A, Karabay CY, et al. Relation of the severity of contrast induced nephropathy to SYNTAX score and long term prognosis in patients treated with primary percutaneous coronary intervention. Int J Cardiol. 2013; 168:3480–3485.
8. Elbasan Z, Şahin DY, Gür M, et al. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology. 2014; 65:37–42.
9. Wang G, Wang C, Zhang Y, et al. Usefulness of the SYNTAX score II to predict 1-year outcome in patients with primary percutaneous coronary intervention. Coron Artery Dis. 2016; 27:483–489.
10. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Steg PG, James SK, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33:2569–2619.
11. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol. 2003; 181:1463–1471.
12. Kim SM, Tripathy DR, Park SW, et al. Impact of chronic kidney disease on clinical outcomes in diabetic patients undergoing percutaneous coronary intervention in the era of newer-generation drug-eluting stents. Korean Circ J. 2017; 47:222–230.
13. SYNTAX Working Group. SYNTAX score calculator [Internet]. [place unknown]: SYNTAX Working Group;cited 2016 September 25. Available from:
http://www.syntaxscore.com.
14. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005; 1:219–227.
15. Magro M, Nauta S, Simsek C, et al. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: the MI SYNTAX score study. Am Heart J. 2011; 161:771–781.
16. Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013; 381:639–650.
17. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996; 93:879–888.
18. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3:32–35.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44:837–845.
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27:157–172.
21. Tziakas D, Chalikias G, Stakos D, et al. Development of an easily applicable risk score model for contrast-induced nephropathy prediction after percutaneous coronary intervention: a novel approach tailored to current practice. Int J Cardiol. 2013; 163:46–55.
22. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002; 105:2259–2264.
23. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005; 95:13–19.
24. Harjai KJ, Raizada A, Shenoy C, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol. 2008; 101:812–819.
25. Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med. 2016; 164:406–416.
26. John S, Schmieder RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep. 2003; 5:199–207.
27. Aykan AÇ, Gül I, Gökdeniz T, et al. Is coronary artery disease complexity valuable in the prediction of contrast induced nephropathy besides Mehran risk score, in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention? Heart Lung Circ. 2013; 22:836–843.
28. Fu NK, Yang SC, Chen YL, et al. Risk factors and scoring system in the prediction of contrast induced nephropathy in patients undergoing percutaneous coronary intervention. Zhonghua Yi Xue Za Zhi. 2012; 92:551–554.
29. Vuruşkan E, Saraçoğlu E. Bilirubin levels are associated with contrast-induced nephropathy in peripheral artery disease. Angiology. 2017; 68:728–733.